Immunomedics (NASDAQ:IMMU) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Thursday.
Other research analysts have also issued research reports about the stock. TheStreet upgraded shares of Immunomedics from a “d” rating to a “c-” rating in a research note on Friday, February 9th. Zacks Investment Research lowered shares of Immunomedics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 15th. ValuEngine lowered shares of Immunomedics from a “hold” rating to a “sell” rating in a research note on Monday, December 4th. Finally, Jefferies Group upped their price target on shares of Immunomedics from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $19.00.
Immunomedics (IMMU) opened at $17.01 on Thursday. Immunomedics has a 52 week low of $4.73 and a 52 week high of $18.93. The company has a market cap of $2,713.88, a PE ratio of -8.42 and a beta of 1.50. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 1.20.
Several large investors have recently made changes to their positions in IMMU. NEA Management Company LLC acquired a new position in shares of Immunomedics during the 3rd quarter worth approximately $38,762,000. Palo Alto Investors LLC grew its position in shares of Immunomedics by 58.6% during the 4th quarter. Palo Alto Investors LLC now owns 4,774,261 shares of the biopharmaceutical company’s stock worth $77,152,000 after purchasing an additional 1,763,795 shares in the last quarter. ArrowMark Colorado Holdings LLC grew its position in shares of Immunomedics by 48.5% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 5,225,124 shares of the biopharmaceutical company’s stock worth $84,438,000 after purchasing an additional 1,705,624 shares in the last quarter. State Street Corp grew its position in shares of Immunomedics by 37.2% during the 2nd quarter. State Street Corp now owns 4,818,847 shares of the biopharmaceutical company’s stock worth $42,549,000 after purchasing an additional 1,305,298 shares in the last quarter. Finally, Lord Abbett & CO. LLC acquired a new position in shares of Immunomedics during the 2nd quarter worth approximately $10,570,000. Hedge funds and other institutional investors own 72.69% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/24/immunomedics-immu-stock-rating-upgraded-by-bidaskclub.html.
Immunomedics Company Profile
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.